HYDRATE IT
with Juvéderm® VOLITE 1,*
SMOOTH IT
with Juvéderm® VOLBELLA2,*
FILL IT
with Juvéderm® VOLIFT 3,*
VOLUMISE IT
with Juvéderm® VOLUMA4,*
SCULPT IT
with Juvéderm® VOLUX 5,*
Model treated with JUVÉDERM®. Results may vary. * Products contain lidocaine,1–5 the addition of which does not alter the physical properties of JUVÉDERM® products.6 In this document, Juvéderm® VOLBELLA with lidocaine, Juvéderm® VOLIFT with lidocaine and Juvéderm® VOLUMA with lidocaine will be referred to as Juvéderm® VOLBELLA, Juvéderm® VOLIFT and Juvéderm® VOLUMA, respectively.
VAL! AR R I
OUR COMPREHENSIVE COLLECTION OF FILLERS1–5 IS DESIGNED AND TAILORED FOR THE MOST TREATED AREAS OF THE FACE 7,*
N EW
DISCOVER® IT WITH THE VYCROSS COLLECTION Compared with HYLACROSS® technology, VYCROSS® technology offers: •
Lower gel swelling,8 which may help prevent overcorrection post-injection9
•
Thorough tissue integration,10–13,† which may contribute to the natural look and feel assessed as a result of treatment10,11,14,15
•
Duration from 9 to 24 months, depending on which filler you choose14,16–20
Injection site responses across the collection are mostly mild-to-moderate in severity.16–19,21,22
Juvéderm® VOLUX – our most cohesive, 23,‡ elastic, 24,‡ concentrated HA gel in the VYCROSS® collection5 – is here! Juvéderm® VOLUX has been designed to restore and create volume in the chin and jaw area.20,§
* Based on market research involving 756 healthcare professionals from 12 must-win markets.7 † Tissue integration was demonstrated by Juvéderm® VOLBELLA, Juvéderm® VOLIFT, Juvéderm® VOLUMA and Juvéderm® VOLUX at 4 weeks in animal in vivo studies.10–13 ‡ Rheological properties of gels are characteristics to describe their physical responses to applied forces in vitro and should not be individually translated to clinical performance. 23,24 § Clinical study assessed lower face as chin and jaw area. 20
Images are for illustrative purposes only. Not an accurate representation of the data.
When you want to enhance skin quality 1,17,25,*
When you want to fill lines and shape features3
When you want to refine features and reduce fine lines2,14
When you want to correct mid-face volume4,16,18
When you want to define the lower face5,20,26,†
+ hands + décolletage
Duration
(months)14,16–21,27–29
Injection depth1–5 HA concentration (mg/mL) + 0.3% lidocaine1–5
Extrusion force at 50 mm/min (N)30,‖
9
‡
Intradermal
12 19.7
32G1/2” needle
§
12
18
Superficial Mid-dermis Lips mucosa
Deep dermis Lips mucosa
15 13.8
30G1/2” needle
18 – 24
Subcutaneous Deep dermis Upper periostea
Subcutaneous Supraperiostal
17.5 18.6
30G1/2” needle
¶
24
20 15.8
27G1/2” needle
25 16.5
27G1/2” needle
Cohesivity
12
18
24
35
93
Elasticity
166
274
317
353
665
(grams-force [gmf])23,**
(G’ at 5 Hz, pascals [Pa]24,**
Lift capacity31 HA, hyaluronic acid. Duration dependent on treatment area. * Skin quality is defined as smoothness (absence of fine lines), hydration and elasticity.17 Investigator-assessed cheek skin texture (primary endpoint) as a measure of skin smoothness improved in patients at Month 1 (96.2%), Month 4 (76.3%), Month 6 (34.9%) and Month 9 (15.8%).17 † Clinical study assessed lower face as chin and jaw area. 20 ‡ Studies evaluating the duration of Juvéderm® VOLITE used Juvéderm® VOLITE B (without lidocaine). 29
§ 18-month duration in nasolabial folds (NLFs) from clinical data. Within 4 weeks after the Month 9, 12, or 15 visits, patients could request a single, unilateral treatment to correct clinically significant asymmetry (at least 1-point difference in NLF severity between NLFs, based on the Evaluating Investigator assessment).19 ¶ Based on comparative preclinical in vitro testing and results from repeat treatment data, added to Juvéderm® VOLUX clinical study showing duration beyond 18 months after initial treatment or initial + top-up treatment in the chin and jaw, as well as clinical results for predicate device Juvéderm® VOLUMA
with lidocaine showing 24 month duration in the mid-face established Juvéderm® VOLUX as having an in situ duration of 18–24 months. 28 ‖ An extrusion force of <20 N is classified as ‘low’ when injected at a fixed rate of 50 mm/min.30 Extrusion force of gels is a characteristic to describe their physical responses to applied forces upon injection and should not be individually translated into clinical performance.30 ** Rheological properties of gels are characteristics to describe their physical responses to applied forces in vitro and should not be individually translated to clinical performance. 23,24
JUVÉDERM® IT WITH THE NUMBER ONE BRAND OF HYALURONIC ACID (HA) FACIAL FILLERS 32,* The VYCROSS® collection uses tailored technology vs HYLACROSS®33,34
Give patients natural-looking changes14,15 with lasting results17,20,33,35 and satisfaction14,17,20
Create bespoke treatment plans by choosing one or more fillers1–5 For illustrative purposes only.
For illustrative purposes only.
References 1. Juvéderm® VOLITE DFU. 73140JR11. Revision 2017-07-19. 2. Juvéderm® VOLBELLA with lidocaine DFU. 72525JR12. Revision 2017-07-19. 3. Juvéderm® VOLIFT with lidocaine DFU. 72383JR14. Revision 2017-07-19. 4. Juvéderm® VOLUMA with lidocaine DFU. 72475JR13. Revision 2017-07-19. 5. Juvéderm® VOLUX DFU. 72778JR10. Revision 2018-07-26. 6. Raspaldo H et al. J Cosmet Dermatol. 2010;9:11–15. 7. Allergan. Unpublished Data. INT/0023/2017(1). The most treated areas of the face. Feb 2019. 8. Allergan. Unpublished Data. INT/0013/2018a(1). JUVÉDERM ® gel swell data. May 2018. 9. Kablik J et al. Dermatol Surg. 2009;35(Suppl 1):302–12. 10. Hee CK et al. Dermatol Surg. 2015;41(Suppl 1):S373–81. 11. Allergan. Data on File. INT/0663/2018. Juvéderm® VOLUX final clinical evaluation report. Oct 2018. 12. Allergan. Data on File. INT/0650/2017. JUVÉDERM® tissue integration images. Aug 2017. 13. Allergan. Unpublished data. INT/0314/2018(1). Juvéderm® VOLUX tissue integration. May 2018.
Allergan Norden AB, Strandbergsgatan 61, 112 51 Stockholm, Sverige To report Adverse Events please contact: ProductSurveillance_EAME@Allergan.com
14. Eccleston D and Murphy DK. Clin Cosmet Investig Dermatol. 2012;5:167–72. 15. Philipp-Dormston WG et al. J Cosmet Dermatol. 2014;13:125–34. 16. Callan P et al. Clin Cosmet Investig Dermatol. 2013;6:81–89. 17. Niforos F et al. Poster Presentation at Beauty Through Science (BTS) Congress, Stockholm, Sweden; 2017. 18. Jones D and Murphy DK. Dermatol Surg. 2013;39:1602–12. 19. Allergan. Unpublished Data. INT/0214/2017(2). Juvéderm® VOLIFT XC US clinical study results (V17-001). Apr 2019. 20. Allergan. Data on File. INT/0654/2018. Juvéderm® VOLUX final clinical study report & clinical evaluation report – efficacy and duration data. Oct 2018. 21. Niforos F et al. Dermatol Surg. 2017;43:1271–80. 22. Allergan. Data on File. INT/0661/2018. Juvéderm® VOLUX final clinical study report – safety data. Oct 2018. 23. Allergan. Unpublished Data. INT/0011/2018a(1). JUVÉDERM ® gel cohesivity data. May 2018. 24. Allergan. Unpublished Data. INT/0141/2019. JUVÉDERM ® (gel elasticity G’) data. Mar 2019. 25. Allergan. Unpublished Data. INT/0078/2017(1). Juvéderm® VOLITE treatment area. Mar 2019.
26. Ogilvie P et al. Poster Presentation at Aesthetic & Anti-Aging Medicine World Congress (AMWC), Monte Carlo, Monaco; 2018. 27. Allergan. Data on File. INT/0607/2017. Juvéderm® VOLIFT NLFSS responder rates (S17L-001). Aug 2017. 28. Allergan. Data on File. INT/0074/2019. Juvéderm® VOLUX final clinical evaluation report. Jan 2019. 29. Allergan. Data on File. INT/0773/2016(1). Juvéderm® VOLITE B without lidocaine. Sep 2018. 30. Allergan. Unpublished Data. INT/0009/2018(1)a(1). JUVÉDERM ® extrusion force data. May 2018. 31. Allergan. Unpublished Data. INT/0129/2019. Juvéderm® VYCROSS collection lift capacity. Feb 2019. 32. Allergan. Unpublished Data. INT/0771/2016(2). JUVÉDERM ®, the world’s leading brand of hyaluronic acid facial fillers. Feb 2019. 33. Goodman GJ et al. Plast Reconstr Surg. 2015;136(5 Suppl):139S–48S. 34. Bernardin A et al. Poster Presentation at Anti-Aging Medicine European Congress (AMEC), Monte Carlo, Monaco; 2013. 35. Pinsky MA et al. Aesthet Surg J. 2008;28:17–23.
WWW.JUVEDERM.SE WWW.JUVEDERM.NO
WWW.JUVEDERM.DK WWW.JUVEDERM.FI
JUVEDERMSE JUVEDERMNO
JUVEDERMSE JUVEDERMNO
JUVEDERMDK JUVEDERMFI
JUVEDERMDK JUVEDERMFI
ND/0228/2019. Date of preparation: May 2019
* Based on healthcare professional (HCP) tracking market research, from over 1000 HCPs in the largest 13 aesthetic markets worldwide.32